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Paediatrics, University of Berne, Inselspital, CH-3010 Berne, Switzerland
The efficacy and safety of intravenous and sequential intravenous-oral clavulanate-
potentiated amoxycillin therapy was evaluated in 71 hospitalized paediatric patients,
one month to 16 years of age. The infections treated included peritonsillar abscess
(2 patients), purulent tracheitis (1), acute epiglottitis (24), pneumonia (31),
pansinusitis (4), mastoiditis (1), cellulitis (4), lymphadenitis (2) and pyelonephritis
(2). The severity of disease was rated as moderate in 31 patients (44%), and as
severe in 40 (56%). Bacterial pathogens could be cultured in 26 cases (37%). The
response to therapy was prompt and followed by clinical cure in each patient.
Adverse drug effects included phlebitis (in 6%),.mild gastrointestinal complaints
(6%), rash (4%) and transient neutropenia and elevation of transaminases (one case
each). It is concluded that amoxycillin/clavulanate is effective and safe treatment for
bacterial infections of the respiratory tract, urinary tract, skin or soft tissues in
children.
Introduction
The combination of the /Mactamase inhibitor clavulanic acid with amoxycillin
provides an attractive approach to increasing the clinical utility of amoxycillin in
paediatric patients, since clavulanic acid protects amoxycillin against hydrolysis by
/?-lactamases produced with increasing frequency by many important bacterial
pathogens causing paediatric infectious diseases (Hunter et ah, 1980; Reading, Farmer
& Cole, 1983). Investigators at this institution have studied the pharmacokinetics of
both intravenous and oral amoxycillin/clavulanate formulations in children and have
suggested dosage schedules (Schaad, Casey & Cooper, 1983; Schaad, Casey &
Ravenscroft, 1986). Several clinical trials with oral amoxycillin/clavulanate have
demonstrated that this antimicrobial combination is effective and safe therapy for
various childhood bacterial infections (Jeffries, Rose & Williams, 1983; Gooch et al.,
1985; Odio et al, 1985; Jaffe et al, 1985). However, published experience with
intravenous amoxycillin/clavulanate in paediatric hospital practice is scant (Price &
Horobin, 1985; Ploechl, Pirko & Huber, 1985). Therefore, this open, non-comparative
study was conducted to evaluate the efficacy and safety of intravenous and sequential
intravenous-oral amoxycillin/clavulanate in the treatment of hospitalized children with
various bacterial infections of moderate to severe degree.
Patients and methods
Study patients
Infants and children aged one month to 16 years admitted to the Department of Paediatrics,
University of Berne, for treatment of community acquired infections of suspected
385
0305-7453/87/030385 + 07 $02.00/0 © '987 The British Society for Antimicrobial Chemotherapy
386 U. B. Schaad et al.
bacterial aetiology were candidates for study. The study protocol included the
following disease localizations: upper and lower respiratory tract, soft and lymphoid
tissue, and urinary tract. Patients with a history of allergy to /?-lactam antibiotics or
underlying renal or hepatic dysfunction were excluded. The study was approved by the
Institutional Committee on Human Investigations, Department of Paediatrics,
University of Berne, and informed parental consent was obtained.
Patient evaluation
Complete medical history, comprehensive physical examination and suitable
laboratory, radiological and microbiological studies were performed on each patient.
Patients with findings suggesting non-bacterial disease were excluded from enrollment.
In-vitro susceptibilities of significant pathogens to amoxycillin/clavulanate, amoxycillin
and other antimicrobial agents were determined by a standardized Kirby-Bauer paper
disc technique.
Treatment
Amoxycillin/clavulanate (Augmentin) vials containing 550 mg (500 mg of amoxycillin
plus 50 mg of clavulanic acid) or 11 g (1 g of amoxycillin plus 100 mg of clavulanic
acid) were used. All patients were started on intravenous amoxycillin/clavulanate at a
recommended dosage according to severity of disease of 110 to 220 mg of
amoxycillin/clavulanate/kg body weight/day, divided into four equal doses
administered as bolus iv injection over 2-5 min. Once an unequivocal clinical response
had been established and provided that gastrointestinal function was normal, the
patients were changed to oral amoxycillin/clavulanate therapy. Paediatric oral
amoxycillin/clavulanate formulations (syrup sachets or bottled suspensions) were used
and contained four parts of amoxycillin and one part of clavulanic acid.
Recommended dosages were between 50 and 100 mg of amoxycillin/clavulanate/kg
body weight/day, divided into three equal doses. Duration of therapy was decided by
the physician responsible. The remaining medical therapy was according to standard
procedures.
Evaluation of therapy
Clinical, bacteriological and radiological responses to treatment were evaluated in each
patient. Clinical cure was defined as complete resolution of symptoms with significant
improvement of physical signs. Follow-up bacteriological cultures were done at the
discretion of the physician. Follow-up chest radiographs were performed in all
pneumonia patients. Adverse or toxic reactions to amoxycillin/clavulanate were
assessed by daily clinical observation and haematological and biochemical monitoring
at the beginning and end of treatment.
Results
Patient characteristics and therapies
From March 1985 to February 1986 a total of 71 infants and children were enrolled in
the study. Their sex and age distribution and the daily dosage and duration of iv and
oral amoxycillin/clavulanate therapy are listed in Table I.
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Table I. Patient characteristics, daily dosage and duration of amoxycillin/clavulanate therapy
Characteristic
Sex
Male
Female
Age
1-11 months
1-6 years
> 6 years
Daily dosage of amoxy-
cillin/clavulanate
(mg/kg)
iv (in 4 x /day)
po (in 3 x /day)
Duration of therapy (days)
iv
po
Total
No. patients (%)
45 (63)
26 (37)
8 (11)
44 (62)
19 (27)
71 (100)
64 (90)
Mean (range)
4 11/12(1/12-15 9/12)
174 (76-272)
60(23-110)
4-6 (1-14)
7-2(2-15)
11 1 (5-25)
In 16 patients (23%) the medical history revealed an underlying disease potentially
relevant to the outcome of the infection. Five patients with pneumonia and two with
pansinusitis had psychomotor retardation. Gastrooesophageal reflux was present in
four patients with pneumonia and congenital heart disease could have promoted
pneumonia in two infants. There was one case each with the association of bilateral
vesicoureteric reflux and pyelonephritis, surgically repaired cleft palate and epiglottitis,
and acute lymphoblastic leukaemia and pneumonia.
Nineteen patients (27%) had received unsuccessful antimicrobial therapy either po
(18 patients) or iv (one patient) prior to amoxycillin/clavulanate. In 15 cases the
duration of oral antibiotic administration was only one (12 patients) or two days (three
patients) and their clinical non-response was interpreted as due to inadequate duration
or an unsuitable route. Three of these patients had received oral
amoxycillin/clavulanate. The choice of an unsuitable antibiotic was felt to explain the
clinical failure in two patients: one had received oral co-trimoxazole for cervical
lymphadenitis, and one chloramphenicol for bronchopneumonia. In two patients, in-
vitro resistance of the pathogen was the probable explanation: Haemophilus influenzae
resistant to erythromycin causing lobar pneumonia in one of these, and Escherichia
coli resistant to cefuroxime causing aspiration bronchopneumonia in the other.
Five patients (7%) received other antibiotics in addition to amoxycillin/clavulanate.
Three patients with pneumonia and positive cold agglutinins received oral
erythromycin until negative complement fixation tests for Mycoplasma pneumoniae
were reported after 3, 7 and 10 days. One patient with severe, culture-negative
pansinusitis and a subperiosteal abscess in the right orbital roof was concomitantly
treated with clindamycin iv and the fifth patient with known bilateral vesicoureteral
reflux who had developed severe pyelonephritis due to E. coli also received amikacin
iv. This urine pathogen was sensitive in vitro to amoxycillin/clavulanate and amikacin,
but resistant to amoxycillin.
In the 24 patients with acute epiglottitis immediate nasotracheal intubation was
performed under deep inhalation anaesthesia as described in detail elsewhere (Gerber
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& Pfenninger, 1986). Mean duration of intubation was 23-6 h with a range from 14 to
38 h. There was no complication related to anaesthesia or intubation procedures.
Infections
The various infections requiring antibiotic treatment and their severity are listed in
Table II. The degree of illness was rated as moderate in 31 (44%) and as severe in 40
patients (56%).
Surgical drainage of pus was only necessary in the case of orbital subperiosteal
abscess complicating pansinusitis. Thoracocentesis was performed in all six patients
with pneumonia and pleural effusion (pleuropneumonia): sterile exudates were found
and in no case was there empyema. There was one case of periorbital and three cases
of buccal cellulitis.
Table II. Clinical details of cases
Diagnosis
Peritonsillar abscess
Purulent tracheitis
Acute epiglottitis
Pleuropneumonia
Lobar pneumonia
Bronchopneumonia
Pansinusitis
Mastoiditis
Cellulitis
Lymphadenitis
Pyelonephritis
Total
No. patients (%)
2
1
24
6
15
10
4
1
4
2
2
71
(3)
(15)
(34)
(9)
(21)
(14)
(5)
(1-5)
(5)
(3)
(3)
(100)
Severity
Moderate
1
1
—
2
10
7
3
—
4
2
1
31 (44)
of disease
Severe
1
—
24
4
5
3
1
1
—
—
1
40(56)
Bacteriology
Bacterial pathogens could be cultured from relevant samples in 26 patients (37%). The
isolated pathogens, their source and in-vitro susceptibility, as well as the infections
they caused are shown in Table III. All bacterial isolates were susceptible in vitro to
amoxycillin/clavulanate but four strains were /Mactamase-positive and resistant to
amoxycillin: one Staphylococcus epidermidis strain, two E. coli strains, and one
Klebsiella pneumoniae strain.
Response to therapy
Response to amoxycillin/clavulanate therapy was prompt in each patient and clinical
assessment at the end of treatment and at follow-up revealed cure in all cases. Follow-
up radiographs in the patients with pneumonia, sinusitis and mastoiditis showed
marked resolution of the pathologic radiographic signs before amoxycillin/clavulanate
therapy was discontinued. Because of clinical cure, follow-up cultures were only
performed in two urine (pyelonephritis) and two pus samples (mastoiditis, cellulitis):
both urine and both clear aspirate samples were culture-negative.
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Safety
Clinical adverse effects attributed to amoxycillin/clavulanate were observed in 12
patients (17%). Phlebitis at the injection site in four patients required change of
intravenous access. Four patients experienced gastrointestinal complaints (two with
diarrhoea and vomiting, two with diarrhoea only). However, these were mild side
effects, and in no case was medication discontinued. Three patients developed
maculopapular rashes: at the end of therapy in two cases (days 8 and 14, respectively),
and in one case manifest from day 4 to day 10 of treatment. One patient developed a
generalized urticarial rash on the eighth day of treatment requiring cessation of
therapy.
Complete laboratory monitoring at the beginning and at the end of treatment was
performed in 38 patients (54%). Neutropenia developed in one patient with periorbital
cellulitis (248 neutrophils/^1 on day 6 of therapy) and resolved within three weeks. A
four- and ten-fold rise respectively of the liver enzymes SGOT and SGPT was found in
one patient with lobar pneumonia associated with recurrence of leukaemia and
resolved partially after one week and completely after four weeks.
Discussion
Over the last ten years increasing numbers of /Mactamase-producing bacterial
pathogens (H. influenzae, H. parainfluenzae, Branhamella catarrhalis, staphylococci
and Enterobacteriaceae) have been isolated from paediatric patients with various
infections. Management of these conditions requires an antimicrobial agent that
is resistant to cleavage by the /Mactamases and effective against both Gram-positive
and Gram-negative bacteria. In addition to satisfying these basic in-vitro requirements,
amoxycillin/clavulanate has other major advantages: the amoxycillin component has a
long record of extensive clinical use with favourable results; the two drug constituents
amoxycillin and clavulanic acid are pharmacokinetically compatible after iv and oral
administration and adequate dosage schedules have been established; finally, both
intravenous and oral therapy are possible with the same antibacterial agents (Schaad
et al., 1983; Schaad et al., 1986).
In the present non-comparative study the efficacy and safety of intravenous and
sequential intravenous-oral amoxycillin/clavulanate therapy for various childhood
bacterial infections were evaluated in 71 patients. An underlying disease was present in
23%, unsuccessful antimicrobial therapy prior to amoxycillin/clavulanate had been
administered in 27%, and the degree of illness at hospital admission was rated as
severe in 56% and as moderate in 44%. The response to amoxycillin/clavulanate
therapy was prompt in each patient and all were cured of their infections.
These excellent clinical and bacteriological results with amoxycillin/clavulanate in
paediatric hospital practice compare favourably with previous reports with oral
amoxycillin/clavulanate in general paediatric practice (Jeffries et al., 1983), in
childhood pneumonia (Gooch et al., 1985), otitis media (Odio et al., 1985) and skin
and soft tissue infections (Jaffe et si., 1985). Also the limited data reported with
intravenous amoxycillin/clavulanate in paediatric infections (Price & Horobin, 1985;
Ploechl et al., 1985) are in agreement with the findings in this study.
Clinical adverse effects attributed to amoxycillin/clavulanate were infrequent and
usually mild: in only one case of urticarial rash was cessation of therapy necessary. The
observed 6% frequency of gastrointestinal complaints (diarrhoea with and without
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vomiting) with amoxycillin/clavulanate lies at the lower end of frequencies reported
elsewhere: 2-5% (Price & Horobin, 1985), 8% (Jeffries et al, 1983), 9% (Jaffe et al.,
1985), 15% (Gooch et al., 1985), and 24% (Odio et al., 1985). A rash is observed in 1
to 5% of children who receive aminopenicillins (McCracken, 1983); in this study four
patients (6%) developed rashes most probably related to drug therapy. There was one
case each of transient neutropenia and temporary increase of hepatic enzymes.
Whether the neutropenia and disturbed hepatic function were due solely to
amoxycillin/clavulanate or to a multiplicity of factors is uncertain.
It is concluded that intravenous and sequential intravenous-oral
amoxycillin/clavulanate are safe and highly effective treatments for paediatric patients
admitted to hospital with respiratory tract, urinary tract, skin and soft tissue
infections.
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